<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DICHLORPHENAMIDE</span><br/>(dye-klor-fen'a-mide)<br/><span class="topboxtradename">Daranide, </span><span class="topboxtradename">Oratrol<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">carbonic anhydrase inhibitor</span>; <span class="classification">antiglaucoma</span><br/><b>Prototype: </b>Acetazolamide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonbacteriostatic sulfonamide derivative similar to acetazolamide except that chloride excretion is increased, and thus potential
         for significant metabolic acidosis is less.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers IOP by decreasing production of aqueous humor.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive treatment of open-angle glaucoma and preoperatively in narrow-angle glaucoma when delay of surgery is desired to
         lower IOP. Commonly used in conjunction with a miotic; an osmotic agent may also be used to enhance reduction of IOP in acute
         angle-closure glaucoma.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sulfonamides and sulfonamide derivative diuretics; depressed sodium and potassium levels, severe pulmonary
         obstruction, marked kidney or liver dysfunction, hyperchloremic acidosis, adrenocortical insufficiency, long-term use in noncongestive
         angle-closure glaucoma. Safe use during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Respiratory acidosis, reduced respiratory capacity, diabetes mellitus.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Glaucoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100200 mg followed by 100 mg q12h until desired response is obtained <span class="rdroute">PO Maintenance Dose:</span> 2550 mg 13 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Take drug with meals to reduce gastric irritation.</li>
<li>Store at room temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Paresthesia, sedation, drowsiness, fatigue, dizziness, ataxia. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, metallic taste, diarrhea, abdominal discomfort. <span class="typehead"> Hematologic:</span>  Leukopenia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, hemolytic anemia. <span class="typehead">Urogenital:</span> Urinary frequency, crystalluria, renal calculi.  <span class="typehead">Skin:</span>  Urticaria, pruritus, rash. <span class="typehead">Other:</span> Weight loss, fever, glycosuria, asymptomatic hyperuricemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Renal excretion of <span class="classification">amphetamines</span>, <b>ephedrine,</b> <b>flecainide,</b> <b>quinidine,</b> <b>procainamide,</b> <span class="classification">tricyclic antidepressants</span> may be decreased, thereby enhancing or prolonging their effects; increases renal excretion of <b>lithium;</b> excretion of <b>phenobarbital</b> may be increased; <b>amphotericin B,</b> <span class="classification">corticosteroids</span> may increase <b>potassium</b> loss; dichlorphenamide-induced hypokalemia may predispose patients taking <span class="classification">digitalis glycosides</span> to <b>digitalis</b> toxicity; patients on high doses of <span class="classification">salicylates</span> are at higher risk for <span class="classification">salicylate</span> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract. <span class="typehead">Onset:</span> 0.51 h. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Duration:</span> 612 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation since drug may cause dizziness and ataxia; other safety precautions may be warranted.</li>
<li>Monitor for hematologic reactions common to sulfonamides. Obtain baseline CBC and platelet counts before initiating therapy
            and at regular intervals.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Increase fluid intake to a high level to reduce risk of renal calculi. Consult physician.</li>
<li>Report to physician the onset of sore throat, fever, unusual bleeding or bruising, tremors, flank or loin pain, skin rash.</li>
<li>Do not drive or engage in other potentially hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>